The University of Tokyo

Hiroshima University

Tokyo University of Pharmacy & Life Sciences

Shionogi Company Limited

Tohoku University

Riken Corporation

Amenis Bioscience, Inc.

Amenis Biosciences, Inc.

Takayoshi Okabe

Tetsuo Nagano

Hirotatsu Kojima

Tomoichiro Asano

Yusuke Nakatsu

Hisanaka Ito

Nobuyuki Tanaka

Osamu Nureki

Hiroshi Nishimasu

Ryuichiro Ishitani

Yusuke Tateno

Junken Aoki

Mitsuyasu Kawaguchi

Junji Yamane

Shigeyuki Yokoyama

Hirofumi Nakano

Akiko Tanaka

Manabu Katou

Shiro Kida

Hidenori Ichijo

Yasuhiko Kanda

Masanao Abe

Takao Fujisawa

Chiaki Fujikoshi

Keiko Tsuganezawa

Tsunehiko Higuchi

Hitomi Yuki

Teruki Honma

Nae Saito

Seiichi Nakamura

Hidehiko Nakagawa

Shin-Ichi Ikeda

Kengo Homma

Naomi Tsuburaya

Masahide Odan

Manabu Shimonishi

Yoshiyuki Kioi

Norio Shiibata

The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.

Anthranilic acid-based compound, and Pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same

The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt. 

Amide compound, and Pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same

An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound. 

Ester compound and PIN1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used

The purpose of the invention is to develop a novel therapeutic agent for fatty liver diseases such as NASH or NAFLD. The invention provides a therapeutic or prophylactic agent for fatty liver diseases that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a therapeutic or prophylactic agent for adiposity that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. 

Therapeutic agent for fatty liver diseases and therapeutic agent for adiposity

A compound represented by the following formula (1) is provided: wherein X represents a sulfur atom or &#x2014;CH&#x2550;CH&#x2014;; Ato Aeach independently represent a carbon atom or a nitrogen atom, and at least one of Ato Ais a nitrogen atom; Rrepresents any one of a 1,2,3,4-tetrahydroquinolyl group (or a 3,4-dihydro-1(2H)-quinolyl group), a 3,4-dihydro-4,4-dimethyl-1(2H)-quinolyl group, a 2,3,4,5-tetrahydro-1H-1-benzazepinyl group, or a substituent represented by the following formula (2): wherein Rrepresents a 2,3,4-trifluorophenyl group, a 4-iodophenyl group, a 2,3-difluorophenyl group, a 3,5-difluorophenyl group, a 5-fluoro-2-methylphenyl group, a 3-pentafluorosulfanylphenyl group, a 2,6-dimethylphenyl group, a 4-benzyloxyphenyl group, a 3,5-bis(trifluoromethyl)biphenyl group, a 4-tert-butylphenyl group, a 3-methoxyphenyl group, an unsubstituted or substituted pyridyl group, or an unsubstituted or substituted naphthyl group; Rrepresents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group optionally containing an oxygen atom and/or a double bond, or an unsubstituted or substituted aromatic lower alkyl group; Rrepresents a hydrogen atom, a lower alkyl group, a lower acyl group, or an unsubstituted or substituted aromatic lower alkyl group; and Rrepresents a hydrogen atom, or Rand Rmay bind to each other to form a ring.

Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof

The present invention provides a compound of formula (1), wherein R, R, R, R, R, Rand Rare as defined in the description, which has an autotaxin inhibitory activity, a pharmaceutical composition comprising the compound as an active ingredient, and a method of prevention or treatment of a disease involving autotaxin, which is characterized by administering the compound. 

Fused pyrazole derivative having autotaxin inhibitory activity

A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt: 

Pyrimidinone derivative having autotaxin-inhibitory activity

An anticancer agent comprising a compound represented by the formula (I) [Rrepresents hydrogen atom, hydroxyl group, a Calkoxy group and the like; Rand Rrepresents hydrogen atom, a halogen atom, a Calkyl group and the like; Rrepresents hydrogen atom, a Calkyl group, a Calkylsulfonyl group and the like; Rrepresents hydrogen atom or a substituent;represents a single bond or a double bond; Rand Rrepresents hydrogen atom, a Calkyl group and the like; Rrepresents hydrogen atom, a Calkyl group and the like; A represents &#x2014;O&#x2014;, &#x2014;S&#x2014;, or &#x2014;CH&#x2014;; D represents &#x2014;C&#x2550; or &#x2014;N&#x2550;; X represents methylene group, &#x2014;O&#x2014;, or &#x2014;CO&#x2014;; Q represents &#x2014;N&#x2550; or &#x2014;C(R)&#x2550;; and Y represents a heterocyclic group or amino group], which shows a superior inhibitory activity against pim-1 kinase. 

Anticancer agent

Growing community of inventors

Tokyo, Japan

Takayoshi Okabe